CD4 and neoplasm: Tumor-infiltrating lymphocytes (TILs) are increasingly recognized for their role in TNBC prognosis, and TME remodeling (recruitment of CD4+ T cells, CD8+ T cells, and NK cells) can enhance the efficacy of immunotherapy (52–55).